Zealand Pharma AS ZLDPF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
A new wave of weight-loss therapies aims to be better than today's GLP-1s
This Danish biotech's new weight-loss drug disappointed investors, and its stock is tumbling
Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
Trading Information
- Previous Close Price
- $35.38
- Day Range
- $34.60–34.60
- 52-Week Range
- $33.08–83.12
- Bid/Ask
- $21.59 / $50.53
- Shares Outstanding
- 66.33M
- Market Cap
- $2.44B
- Volume/Avg
- 300 / 1,240
Key Statistics
- Price/Earnings (Normalized)
- 6.06
- Price/Sales
- 3.39
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 3.66%
Company Profile
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 578
Valuation
Metric | ZLDPF |
|---|---|
Price/Earnings (Normalized) | 6.06 |
Price/Book Value | 0.87 |
Price/Sales | 3.39 |
Price/Cash Flow | 9.23 |
Price/Earnings
ZLDPF
Financial Strength
Metric | ZLDPF |
|---|---|
Quick Ratio | 13.76 |
Current Ratio | 13.98 |
Interest Coverage | 92.71 |
Quick Ratio
ZLDPF
Profitability
Metric | ZLDPF |
|---|---|
Return on Assets (Normalized) | 17.40% |
Return on Equity (Normalized) | 18.94% |
Return on Invested Capital (Normalized) | 16.47% |
Return on Assets
ZLDPF
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|j@Ctyxh | LOCK|PG@p | $139B | |||
| Moderna Inc MRNA | LOCK|^l&fcH | LOCK|Br | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%s$!d?Q | LOCK|?V<&v | $94B | |||
| argenx SE ADR ARGX | LOCK|n%D@jx | LOCK|&$ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|>L?&w>K | LOCK|RH | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|pMZ<^#x | LOCK|P?!J | $30B | |||
| Incyte Corp INCY | LOCK|yPHT?k | LOCK|#N% | $24B | |||
| BioNTech SE ADR BNTX | LOCK|hP%n??Q | LOCK|Hl | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|BlsB?XT | LOCK|T$drg | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|b?<p^% | LOCK|@J@ | $15B |
United States